Table 1.
Cohort demographics, clinical and cancer disease characteristics (n = 1626)
| Characteristic | All patients (n = 1626) |
|---|---|
| Demographics | |
| Sex, n (%) | |
| Female | 845 (52.0) |
| Male | 757 (46.6) |
| Unknown/missing | 24 (1.5) |
| Age (years at COVID-19 diagnosis), n (%) | |
| ≤49 | 303 (18.6) |
| 50-69 | 735 (45.2) |
| ≥70 | 563 (34.6) |
| Unknown/missing | 25 (1.5) |
| Median (Q1-Q3) | 64 (53-73) |
| Ethnicity, n (%) | |
| Caucasian | 942 (57.9) |
| Non-Caucasian | 466 (28.7) |
| Asian | 117 (7.2) |
| Othera | 349 (21.5) |
| Unknown/missing | 218 (13.4) |
| ECOG performance status, n (%) | |
| 0 | 342 (21.0) |
| 1 | 758 (46.6) |
| 2 | 273 (16.8) |
| ≥3 | 114 (7.0) |
| Unknown/missing | 139 (8.5) |
| Smoking history, n (%) | |
| Current smoker | 148 (9.1) |
| Former smoker | 373 (22.9) |
| Never smoker | 658 (40.5) |
| Unknown/missing | 447 (27.5) |
| BMI (kg/m2), n (%) | |
| Underweight (<18.5) | 57 (3.5) |
| Normal (18.5 ≤ BMI < 25) | 490 (30.1) |
| Overweight (25 ≤ BMI < 30) | 502 (30.9) |
| Obesity (≥30) | 280 (17.2) |
| Unknown/missing | 297 (18.3) |
| Median (Q1-Q3) | 25 (22-29) |
| Clinical characteristics | |
| Number of comorbidities, n (%) | |
| 0 | 447 (27.5) |
| 1 | 510 (31.4) |
| >1 | 624 (38.4) |
| Unknown/missing | 45 (2.8) |
| Number of concomitant medications, n (%) | |
| 0 | 501 (30.8) |
| ≥1 | 956 (58.8) |
| Unknown/missing | 169 (10.4) |
| Cancer disease characteristics | |
| Date of cancer diagnosis, n (%) | |
| Within the past year | 758 (46.6) |
| Within the past 5 years | 552 (33.9) |
| More than 5 years ago | 210 (12.9) |
| Unknown/missing | 106 (6.5) |
| Primary tumour type, n (%) | |
| Breast | 332 (20.4) |
| Colorectal | 234 (14.4) |
| Lung | 221 (13.6) |
| Other solid tumour | 619 (38.1) |
| Haematological malignancy | 151 (9.3) |
| Unknown/missing | 69 (4.2) |
| Cancer status at COVID-19 diagnosis, n (%) | |
| Active disease, complete response | 56 (3.4) |
| Active disease, partial response | 129 (7.9) |
| Active disease, stable disease | 519 (31.9) |
| Active disease, progressive disease | 368 (22.6) |
| NED | 335 (20.6) |
| Unknown/missing | 219 (13.5) |
| Cancer stage at COVID-19 diagnosis, n (%) | |
| I | 65 (4.0) |
| II | 162 (10.0) |
| III | 242 (14.9) |
| IV | 688 (42.3) |
| Not applicableb | 395 (24.3) |
| Unknown/missing | 74 (4.6) |
| On anticancer treatment at COVID-19 diagnosis, n (%) | |
| Yes (up to 3 months prior to COVID-19 diagnosis) | 1053 (64.8) |
| No | 424 (26.1) |
| Unknown/missing | 149 (9.2) |
| Past systemic treatment, n (%) | |
| Yes | 707 (43.5) |
| No | 661 (40.7) |
| Unknown/missing | 258 (15.9) |
BMI, body mass index; COVID-19, coronavirus disease 2019; ECOG, Eastern Cooperative Oncology Group; NED, no evidence of disease.
Current smoker: exposed to active smoking; Former smoker: previously exposed to active smoking; Never smoker: never exposed to active smoking.
a
Including African, Arab/Middle Eastern, Latino American, Mediterranean, Pacific Islander/Māori and other.
b
The ‘not applicable’ cancer stage category includes cases for which cancer stage could not be determined: due to patient’s cancer type or because cancer restaging was not available.